MetaCap

Bausch Health Companies (BHC) vs Dyne Therapeutics (DYN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Bausch Health Companies (BHC) has outperformed Dyne Therapeutics (DYN) over the past year, gaining 36.3% versus a loss of 26.8%. Over five years, DYN leads with a +5.4% price change compared with -67.4% for BHC. Bausch Health Companies is the larger company by market cap ($3.08 billion vs $2.90 billion), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BHC+36.32%DYN-26.82%
+52%+8%-37%
Nov 21, 20251 yearNov 20, 2026
BHC-68.40%DYN-1.84%
+209%+56%-97%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BHC versus DYN key metrics
MetricBHCDYN
Share price$8.22$15.50
Market cap$3.08B$2.90B
1-day change-3.97%-3.31%
YTD return+18.27%-20.76%
1-year return+36.32%-26.82%
5-year return-67.45%+5.37%
Forward P/E1.89—
EPS (TTM)$-2.26$-3.62
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$10.27B—
Revenue growth (YoY)+6.66%—
Net income (latest FY)$157.00M$-446.21M
Operating margin17.66%—
Net margin1.53%—
52-week high$9.04$27.31
52-week low$4.33$14.00
Distance from 52-week high-9.07%-43.23%
Analyst consensusholdstrong_buy
Avg. price target upside+2.19%+121.48%
Average volume3.16M2.94M
Shares outstanding374.27M187.39M
Employees20,300322
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • BHC has outperformed DYN by 63.1 percentage points over the past year.

About Bausch Health Companies

BHC stock →

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company.

Health Care · Biotechnology: Pharmaceutical Preparations · 20,300 employees

About Dyne Therapeutics

DYN stock →

Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.

Health Care · Biotechnology: Pharmaceutical Preparations · 322 employees

BHC vs DYN FAQ

Which is bigger, Bausch Health Companies or Dyne Therapeutics?

Bausch Health Companies (BHC) is larger, with a market capitalization of $3.08B compared with $2.90B for Dyne Therapeutics (DYN).

Which stock has performed better over the past year, BHC or DYN?

BHC returned +36.32% over the past 12 months, compared with -26.82% for DYN (price return, excluding dividends). Past performance does not predict future results.

Are Bausch Health Companies and Dyne Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons